Cutaneous mucormycosis in tornado survivors

Current Fungal Infection Reports

Volumn 5, Issue 4, 2011, Pages 187-189

  Lewis, Russell E ^a  

^a UNIVERSITY OF HOUSTON   (United States)

Author keywords

Apophysomyces; Cutaneous mucormycosis; Fungal infection; Joplin; Necrotizing soft tissue infection; Tornado; Trauma; Treatment

Indexed keywords

EID: 84905104560     PISSN: 19363761     EISSN: 1936377X     Source Type: Journal    
DOI: 10.1007/s12281-011-0068-4     Document Type: Review

References (24)

1. National Oceanic and Atmospheric Association. Tornado information. In: http://www.noaanews.noaa.gov/2011-tornado-information.html. 2011. Accessed August 10, 2011.
2. Holm E. Joplin tornado may cost insurers up to 3 billion. Wall Str J. 2011; http://online.wsj.com/article/BT-CO-20110524-707969.html.
3. Centers for Disease Control. Fatal fungal soft-tissue infections after a tornado - Joplin, Missouri, 2011. MMWR Recomm Rep. 2011;60(29):992.
4. Alvarez E, Stchigel AM, Cano J, Sutton DA, Fothergill AW, Chander J, et al. Molecular phylogenetic diversity of the emerging mucoralean fungus Apophysomyces: proposal of three new species. Rev Iberoam Micol. 2010;27(2):80-9. doi:10.1016/j.riam.2010.01.006.
5. Gomes MZ, Lewis RE, Kontoyiannis DP. Mucormycosis caused by unusual mucormycetes, non-Rhizopus, -Mucor, and -Lichtheimia species. Clin Microbiol Rev. 2011;24(2):411-45. doi:10.1128/CMR.00056-10.
6. Alexander BD, Schell WA, Siston AM, Rao CY, Bower WA, Balajee SA, et al. Fatal Apophysomyces elegans infection transmitted by deceased donor renal allografts. Am J Transplant. 2010;10(9):2161-7. doi:10.1111/j.1600-6143.2010. 03216.x.
7. Lakshmi V, Rani TS, Sharma S, Mohan VS, Sundaram C, Rao RR, et al. Zygomycotic necrotizing fasciitis caused by Apophysomyces elegans. J Clin Microbiol. 1993;31:1368-9. (Pubitemid 23129482)
8. Mathews MS, Raman A, Nair A. Nosocomial zygomycotic post-surgical necrotizing fasciitis in a healthy adult caused by Apophysomyces elegans in south India. J Med Vet Mycol. 1997;35(1):61-3. (Pubitemid 27085385)
9. Chakrabarti A, Ghosh A, Prasad GS, David JK, Gupta S, Das A, et al. Apophysomyces elegans: an emerging zygomycete in India. J Clin Microbiol. 2003;41(2):783-8. (Pubitemid 36184197)
10. Chakrabarti C, Sood SK, Parnell V, Rubin LG. Prolonged candidemia in infants following surgery for congenital heart disease. Infect Control Hosp Epidemiol. 2003;24(10):753-7. (Pubitemid 37309605)
11. Chakrabarti A, Das A, Sharma A, Panda N, Das S, Gupta KL, et al. Ten years' experience in zygomycosis at a tertiary care centre in India. J Infect. 2001;42(4):261-6. doi:10.1053/jinf.2001.0831. (Pubitemid 32700823)
12. Chander J, Kaur J, Attri A, Mohan H. Primary cutaneous zygomycosis from a tertiary care centre in north-west India. Indian J Med Res. 2010;131:765-70.
13. Blair JE, Fredrikson LJ, Pockaj BA, Lucaire CS. Locally invasive cutaneous Apophysomyces elegans infection acquired from snapdragon patch test. Mayo Clin Proc. 2002;77(7):717-20. (Pubitemid 34743049)
14. Lesueur BW, Warschaw K, Fredrikson L. Necrotizing cellulitis caused by Apophysomyces elegans at a patch test site. Am J Contact Dermat. 2002;13(3):140-2. (Pubitemid 34925379)
15. Andresen D, Donaldson A, Choo L, Knox A, Klaassen M, Ursic C, et al. Multifocal cutaneous mucormycosis complicating polymicrobial wound infections in a tsunami survivor from Sri Lanka. Lancet. 2005;365(9462):876-8. doi:10.1016/S0140-6736(05)71046-1. (Pubitemid 40332166)
16. Snell BJ, Tavakoli K. Necrotizing fasciitis caused by Apophysomyces elegans complicating soft-tissue and pelvic injuries in a tsunami survivor from Thailand. Plast Reconstr Surg. 2007;119(1):448-9. doi:10.1097/01.prs.0000233624. 34950.f8. (Pubitemid 46360321)
17. Tragiannidis A, Groll AH. Hyperbaric oxygen therapy and other adjunctive treatments for zygomycosis. Clin Microbiol Infect. 2009;15 Suppl 5:82-6. doi:10.1111/j.1469-0691.2009.02986.x.
18. Almyroudis NG, Sutton DA, Fothergill AW, Rinaldi MG, Kusne S. In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents. Antimicrob Agents Chemother. 2007;51(7):2587-90. doi:10.1128/AAC.00452-07. (Pubitemid 47047341)
19. Guarro J, Chander J, Alvarez E, Stchigel AM, Robin K, Dalal U, et al. Apophysomyces variabilis infections in humans. Emerg Infect Dis. 2011;17(1):134-5.
20. Dannaoui E, Mouton JW, Meis J, Verweij PE. Efficacy of antifungal therapy in a nonneutropenic murine model of zygomycosis. Antimicrob Agents Chemother. 2002;46(6):1953-9. (Pubitemid 34535220)
21. Dannaoui E, Meis J, Loebenberg D, Verweij PE. Activity of posaconazole in treatment of experimental disseminated zygomycosis. Antimicrob Agents Chemother. 2003;47(11):3647-50. (Pubitemid 37345740)
22. Sun QN, Fothergill AW, McCarthy DI, Rinaldi MG, Graybill JR. In vitro activities of posaconazole, itraconazole, voriconazole, amphotericin B, and fluconazole against 37 clinical isolates of zygomycetes. Antimicrob Agents Chemother. 2002;46(5):1581-2. (Pubitemid 34415351)
23. Chakrabarti A, Shivaprakash MR, Curfs-Breuker I, Baghela A, Klaassen CH, Meis JF. Apophysomyces elegans: epidemiology, amplified fragment length polymorphism typing, and in vitro antifungal susceptibility pattern. J Clin Microbiol. 2010;48(12):4580-5. doi:10.1128/JCM.01420-10.
24. Ferguson TD, Schniederjan SD, Dionne-Odom J, Brandt ME, Rinaldi MG, Nolte FS, et al. Posaconazole treatment for Apophysomyces elegans rhino-orbital zygomycosis following trauma for a male with well-controlled diabetes. J Clin Microbiol. 2007;45(5):1648-51. doi:10.1128/JCM.00014-07. (Pubitemid 46762431)